Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25mg and metformin hydrochloride extended-release 2000 mg.
To reduce gastrointestinal adverse reactions caused by metformin, take this medicine once daily with the evening meal.
Take one tablet of this medicine 10/1000 mg extended-release tablet or 25/1000 mg extended-release tablet once daily.
Patients taking this medicine 5/1000 mg extended-release tablet, 12.5/1000 mg extended-release tablet, 5/750mg extended-release tablet, or 12.5/750mg extended-release tablet should take 2 tablets together once daily.
To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually.
⦁ For patients who are unable to achieve adequate glycemic control with metformin alone or in combination with other medicines such as insulin, the recommended initial total daily dose when taking this medicine is empagliflozin 10 mg plus the patient's current metformin dose. If empagliflozin 10 mg is well tolerated but additional glycemic control is needed, the dose of empagliflozin may be increased to 25 mg.
⦁ Patients switching from concomitant empagliflozin and metformin therapy to this medicine should receive their previous doses of empagliflozin and metformin.
When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and the dose appropriately adjusted.
Because dosage adjustment is required according to renal function, assessment of renal function is recommended before starting this medicine and periodically during treatment.
No dosage adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧60 mL/min/1.73 m2].
In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2] who tolerate treatment well and have no other condition that may increase the risk of lactic acidosis, this medicine may be used with adjustment of the metformin hydrochloride dose as follows.
- The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg.
If creatinine clearance (CrCl) decreases to below 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to below 45 ml/min/1.73m2, discontinue this medicine immediately.
In patients 75 years of age and older, consider renal function and the risk of volume depletion.
Improvement of glycemic control in adults with type 2 diabetes mellitus
View approved original textHide original text
This medication is used to assist in blood sugar control for adult patients with type 2 diabetes when used in conjunction with Empagliflozin and Metformin as adjunct therapy to diet and exercise. It is particularly effective for patients who do not achieve sufficient blood sugar control, and should be used under the guidance of a specialist in cases of cardiovascular disease. This medication is effective in improving blood sugar levels and assisting in diabetes management.
How to take
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25mg and metformin hydrochloride extended-release 2000 mg.
To reduce gastrointestinal adverse reactions caused by metformin, take this medicine once daily with the evening meal.
Take one tablet of this medicine 10/1000 mg extended-release tablet or 25/1000 mg extended-release tablet once daily.
Patients taking this medicine 5/1000 mg extended-release tablet, 12.5/1000 mg extended-release tablet, 5/750mg extended-release tablet, or 12.5/750mg extended-release tablet should take 2 tablets together once daily.
To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually.
⦁ For patients who are unable to achieve adequate glycemic control with metformin alone or in combination with other medicines such as insulin, the recommended initial total daily dose when taking this medicine is empagliflozin 10 mg plus the patient's current metformin dose. If empagliflozin 10 mg is well tolerated but additional glycemic control is needed, the dose of empagliflozin may be increased to 25 mg.
⦁ Patients switching from concomitant empagliflozin and metformin therapy to this medicine should receive their previous doses of empagliflozin and metformin.
When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and the dose appropriately adjusted.
Because dosage adjustment is required according to renal function, assessment of renal function is recommended before starting this medicine and periodically during treatment.
No dosage adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧60 mL/min/1.73 m2].
In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2] who tolerate treatment well and have no other condition that may increase the risk of lactic acidosis, this medicine may be used with adjustment of the metformin hydrochloride dose as follows.
- The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg.
If creatinine clearance (CrCl) decreases to below 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to below 45 ml/min/1.73m2, discontinue this medicine immediately.
In patients 75 years of age and older, consider renal function and the risk of volume depletion.
Precautions
This medication consists of two components, Metformin and Empagliflozin, and is primarily used in the treatment of type 2 diabetes.
While taking this medication, there is a rare possibility of serious lactic acidosis occurring, so caution is particularly necessary for patients with impaired kidney function or those with heart or liver disease.
When used with other diabetes medications, hypoglycemic symptoms may occur, so blood sugar levels should be closely monitored.
This medication should not be used in patients with moderate to severe impairment of kidney function, acute kidney injury, dehydration, severe infection, or heart failure.
It should be temporarily discontinued before any examination involving iodine contrast agents, and administration should be resumed only after confirming that kidney function has returned to normal post-examination.
Pregnant women or women who may become pregnant, as well as nursing mothers, should avoid using this medication.
This medication may increase the risk of genital and urinary tract infections, so immediate consultation with healthcare professionals is required if any signs of infection appear.
From the time of use, if symptoms such as hypoglycemia, abdominal pain, muscle pain, difficulty breathing, weakness, or other adverse effects occur, the patient should inform a physician immediately.
Elderly patients or those with compromised kidney function should regularly have their kidney function evaluated, and dose adjustments should be made if necessary.
It is advisable to avoid alcohol consumption while using this medication, and this medication may be temporarily paused in case of dehydration, diarrhea, or vomiting.
This medication should be swallowed whole and should not be chewed or broken, although the tablet shell may be excreted in the stool, which is normal.
If there are other medications being used concurrently, there may be potential for drug interactions, so all medications being taken should be disclosed to healthcare personnel.
In the case of overdose, serious side effects such as lactic acidosis may occur, necessitating immediate treatment at a hospital.
Side effects
Severe lactic acidosis
severe hypoglycemia
hypoglycemia
urinary tract infection
genital infection
increased urination
decreased vitamin B12 and deficiency
ketoacidosis
lactic acidosis
decreased fluid volume
Show 152 moreCollapse
nausea
vomiting
diarrhea
abdominal pain
loss of appetite
constipation
abnormal liver function tests
hepatitis
taste disturbance
itching
rash
hives
erythema
angioedema
dysuria
interstitial nephritis
thirst
increased serum lipids
increased serum creatinine
decreased glomerular filtration rate
nausea
malaise
gastric ulcer
colitis
ischemic colitis
bowel bleeding
chronic gastritis
constipation
gastritis
abdominal discomfort
anal incontinence
dry mouth
gastrointestinal disorders
gastroesophageal reflux disease
oral discomfort
salivary gland pain
headache
dizziness
orthostatic dizziness
drowsiness
facial paralysis
memory disturbances
neuralgia
Parkinsonism
polyneuropathy
sensory disturbances
CNS-origin dizziness
fatigue
peripheral edema
facial edema
peripheral swelling
fever
facial swelling
chills
strange sensations
swelling
pain
pain at the puncture site
vascular stent stenosis
vascular stent thrombosis
chest pain
weight loss
urinary stones
hematuria
overactive bladder
renal mass
urinary retention
abnormal urination
vulvar pruritus
benign prostatic hyperplasia
erectile dysfunction
atrophic vaginitis
cervical dysplasia
cervical inflammation
scrotal pain
sexual dysfunction
vaginal discharge
dyslipidemia
hyperglycemia
hyponatremia
dermal cysts
seborrheic dermatitis
atopic dermatitis
diabetic foot
nummular eczema
sweat rash
sebaceous gland hyperplasia
lumbar spinal canal stenosis
myalgia
limb pain
musculoskeletal chest pain
arthralgia
cervical stenosis
fibromyalgia
flank pain
fracture pain
muscle weakness
osteoarthritis
osteoporosis
rotator cuff syndrome
astigmatism
cataracts
allergic conjunctivitis
blurred vision
corneal erosion
glaucoma
macular fibrosis
eye discomfort
eye congestion
pathological myopia
retinal detachment
retinal crystals
retinal vein occlusion
macular retinal detachment
eyelid swelling
visual impairment
vitreous floaters
vitreous hemorrhage
nasal bleeding
asthma
exertional dyspnea
productive cough
allergic rhinitis
residual sputum
cough
skin lacerations
rib fractures
ligament strain syndrome
angina
palpitations
Prinzmetal angina
coronary artery disease
tachycardia
atherosclerosis
deep vein thrombosis
diabetic vascular diseases
peripheral artery occlusive disease
anxiety
depression
sleep disorders
acute cholecystitis
autoimmune hepatitis
cholelithiasis
hepatitis
otalgia
orthostatic dizziness
dizziness
anemia
lymphadenopathy
hypothyroidism
thyroid nodules
unstable angina
Not everyone experiences these, and they can vary from person to person.
Storage
This medication should be stored in a tightly sealed container to protect from air and moisture, at a cool room temperature between 1 and 30 degrees Celsius.
Appearance and packaging
Appearance
Pink oval extended-release film-coated tablet
Package unit
30 tablets/bottle
Same-ingredient medicines
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety. Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.